Explore advanced flow cytometry and BLI label-free detection techniques for characterizing anti-HER2 antibodies in this 43-minute webinar presented by Kirsty McBain, a Scientist at Sartorius. Learn about high-throughput technologies and powerful analysis capabilities essential for screening and profiling antibody-based therapeutics. Discover the applications of the iQue® advanced flow cytometry platform and Octet BLI label-free detection in antibody discovery workflows. Gain insights into antibody binding kinetics, live-cell competition binding, relative glycosylation, antibody internalization, cytotoxic ADC payload-induced killing, and antibody-dependent cellular phagocytosis. Compare NK ADCC activity between anti-HER2 antibodies and understand how these technologies contribute to the development of novel antibody therapeutics across various disease areas, including cancer and infectious diseases.
Characterization of Anti-HER2 Antibodies Using Advanced Flow Cytometry and BLI Label-Free Detection
Overview
Syllabus
Intro
iQue® 3: Advanced Flow Cytometry Platform
Octet BLI Label-Free Detection: Dip and Read Biosensors
Types of Information Generated Using the Octet Platform
Biosensor Chemistries
Project Workflow
Antibody Binding Kinetics
Live-cell Competition Binding
Competition Between Anti-HER2 Antibodies
Relative Glycosylation of Anti-HER2 Antibodies
iQue® Antibody Internalization Kit
Measuring Cytotoxic ADC Payload Induced Killing
iQue® Human Antibody-Dependent Cellular Phagocytosis (ADCP) Kit
ADCP Kit Gating Strategy
Comparing NK ADCC Activity Between Anti-HER2 Antibodies
Wrap Up and Perspective
Taught by
Labroots
